Selpercatinib Data Underscore Value of Precision Medicine in RET-Driven Lung Cancer

Vivek Subbiah, MD, of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the data from selpercatinib have generated excitement for precision medicine in the treatment landscape for patients with RET-driven lung cancer.

The LIBRETTO-001 study demonstrated promising activity with selpercatinib, the selective RET inhibitor, as treatment of patients with RET-mutant non-small cell lung cancer (NSCLC). Subbiah says that this study generated the enthusiasm in precision oncology for RET-driven NSCLC.

This opens up new areas of precision oncology, as well as the opportunity for precision medicine in patients with RET-driven NSCLC. Approval of this agent furthers the use of selpercatinib in the community setting, Subbiah notes. This now demonstrates proof of principal for selective RET inhibition, so we need to know when patients will receive the most benefit from specific RET targeting, which is upfront, in Subbiah’s personal opinion.